Citius Oncology, Inc.
CTOR
$1.99
$0.105.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.58M | -25.98M | -23.08M | -21.15M | -19.52M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.63M | 8.34M | 8.09M | 8.07M | 8.37M |
| Change in Net Operating Assets | 18.08M | 17.77M | 15.12M | 13.20M | 11.15M |
| Cash from Operations | 126.40K | 126.40K | 126.40K | 126.40K | 0.00 |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.00M | -5.00M | -5.00M | -5.00M | -- |
| Cash from Investing | -5.00M | -5.00M | -5.00M | -5.00M | -- |
| Total Debt Issued | 3.80M | 3.80M | 3.80M | 3.80M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.07M | 1.07M | 1.07M | 1.07M | -- |
| Cash from Financing | 4.87M | 4.87M | 4.87M | 4.87M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.00 | 100.00 | 100.00 | 100.00 | -- |